Cencora Inc (COR) Stock Forecast & Price Target

Cencora is supported by its dominant position in a highly concentrated U.S. pharmaceutical wholesale market, where it and two peers control over 90% of share, while its integrated model extends beyond distribution into commercialization services, specialty logistics, and animal health. Its specialty pharmacy exposure, retina and oncology MSO network, and broader vertical integration should help offset IRA and MFN pricing headwinds, with biosimilar launches seen as a meaningful margin tailwind because they can earn 6-8% margins versus about 1% on branded products and could add roughly $185M in operating income by 2028. The 2021 Alliance Healthcare acquisition strengthened its international footprint, and its deep compliance and DSCSA investments further reinforce its scale advantage even as regulatory and litigation risks remain.

Cencora is viewed negatively because its core pharmaceutical distribution growth is expected to slow to mid-single digits as IRA and MFN pricing pressure compresses wholesaler economics, with roughly $28B of Medicare drug spend potentially facing 40-60% price cuts beginning in 2028. Its attractive specialty-drug franchise still faces intensifying competition from vertically integrated PBM-owned specialty pharmacies, while customer concentration and contract renewal risk with large health systems and retail chains leave revenue visibility vulnerable. Regulatory overhang from FTC scrutiny and a combined 67-75% share in US veterinary distribution further heighten antitrust risk, and low-single-digit gross margins limit the company’s ability to absorb supply-chain, freight, labor, or cybersecurity shocks.